arthritis – Page 2 – Cytonics Corporation

#50🔊Listen To Our CEO Describe Our Science In 40 Seconds

Investor Relations, Our Story, Joey BoseMay 27, 20251KViews 0Likes 0Comments

Cytonics has released a video featuring CEO Joey Bose, explaining how their therapy CYT-108 challenges Big Pharma by targeting osteoarthritis’s root causes, rather than just symptoms. The video discusses past successes with APIC, the science behind their approach, and future strategies. Viewers are encouraged to support the company as potential shareholders.

#49 🦈 When a Shark Asks the Right Questions

Investor Relations, Our StoryMay 14, 20252KViews 0Likes 0Comments

Cytonics CEO Joey Bose discussed their groundbreaking approach to osteoarthritis with investor Kevin O’Leary. The biotech firm has treated over 10,000 patients and developed a therapy, CYT-108, which has completed Phase 1 trials. With $15M raised from 6,000 everyday investors, Cytonics challenges traditional Big Pharma funding models.

#48 🎉Major Milestone: Last Patient Completes Phase 1 Clinical Trial

Investor Relations, Our StoryMarch 31, 20252KViews 0Likes 0Comments

Cytonics has completed its first-in-human trial for CYT-108, a recombinant protease inhibitor for knee osteoarthritis. The 22-patient Phase 1 study focused on safety and efficacy, providing data for an FDA IND application and Phase 2 protocol. This milestone boosts prospects for a disease-modifying therapy and enhances shareholder value.

#47 🪙Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development

Investor Relations, Our StoryMarch 25, 20251KViews 0Likes 0Comments

Cytonics is seeking $24 million to fund a Phase 2 Clinical Study for CYT-108, its innovative osteoarthritis therapy. This fundraising effort, in partnership with StartEngine, utilizes Regulation A+, allowing unaccredited investors to participate. CYT-108 offers unique protease inhibition benefits and builds on the success of its predecessor, the APIC system.

#46 📢 Critical Patent Issuance Protecting Lead Drug Candidate

Investor Relations, Our StoryMarch 8, 20251KViews 0Likes 0Comments

Cytonics Corporation has received US Patent No. US 12,195,521 B2 for its engineered A2M variant, CYT-108. This patent enhances its competitive position by expanding therapeutic applications and securing exclusivity for two decades. It strengthens barriers to entry, increases licensing opportunities, and supports funding initiatives for future product development.

#45 🚨 Major Phase 1 Study Milestone Achieved!

Science Corner, Investor Relations, Our StoryJanuary 17, 20252KViews 0Likes 0Comments

The first nine patients have completed the Phase 1 clinical trial of CYT-108, with no reported adverse events. This biologic therapy aims to treat osteoarthritis by targeting cartilage-degrading enzymes. The company plans to initiate Phase 2 trials and will launch an equity crowdfunding campaign to finance further development.

#44 🎉 Landmark Year For Cytonics: A 2024 Missive

Investor Relations, Our StoryJanuary 1, 20251KViews 0Likes 0Comments

As 2024 ends, Cytonics reflects on remarkable progress in developing their drug CYT-108 for osteoarthritis treatment. The first clinical trial began, greatly aided by a team of orthopedic specialists. Plans for Phase 2 trials are underway, with fundraising efforts expected in early 2025 to support research and development.

#50🔊Listen To Our CEO Describe Our Science In 40 Seconds

#49 🦈 When a Shark Asks the Right Questions

#48 🎉Major Milestone: Last Patient Completes Phase 1 Clinical Trial

#47 🪙Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development

#46 📢 Critical Patent Issuance Protecting Lead Drug Candidate

#45 🚨 Major Phase 1 Study Milestone Achieved!

#44 🎉 Landmark Year For Cytonics: A 2024 Missive

Get fresh updates

Download Exclusive Investor Presentation & Stay Updated